Morgan Stanley Maintains Equal-Weight on Pfizer, Lowers Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Equal-Weight rating on Pfizer (NYSE:PFE) and lowered the price target from $43 to $42.
July 21, 2023 | 10:54 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Pfizer and lowered the price target from $43 to $42.
The lowering of the price target by Morgan Stanley could potentially lead to a negative sentiment among investors, which may put downward pressure on Pfizer's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100